FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1995115699> ?p ?o ?g. }

• W1995115699 abstract "You have accessJournal of UrologyProstate Cancer: Detection and Screening II1 Apr 20101844 ASSOCIATION OF STATIN USE TO SERUM PROSTATE SPECIFIC ANTIGEN LEVELS IN A SCREENING POPULATION Bulent Akduman, Daniel J. Tandberg, Colin O'Donnell, Alexa Hughes, Mark A. Moyad, and E. David Crawford Bulent AkdumanBulent Akduman Zonguldak, Turkey More articles by this author , Daniel J. TandbergDaniel J. Tandberg Aurora, CO More articles by this author , Colin O'DonnellColin O'Donnell Aurora, CO More articles by this author , Alexa HughesAlexa Hughes Aurora, CO More articles by this author , Mark A. MoyadMark A. Moyad Ann Arbor, MI More articles by this author , and E. David CrawfordE. David Crawford Aurora, CO More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2010.02.1783AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Serum prostate-specific antigen (PSA) levels are influenced by androgens. Androgens are synthesized from cholesterol. The use of statins, cholesterol lowering drugs, has increased significantly during the last decade. In this cross-sectional study, we investigate the association between statin use and serum PSA levels in men participating in a prostate cancer screening event. METHODS A cohort of 4903 men who participated in Prostate Cancer Awareness Week screenings in the years 2007 or 2008 were enrolled in this study from multiple clinical institutions. Within this cohort 1379 men (28.2%) were on a statin medication. Participants completed a self-administered questionnaire and received a PSA, total testosterone and total cholesterol blood test. The questionnaire included questions assessing background health information, demographics, and current medication use. Age, race and body mass index (BMI) of the cohort was also recorded. PSA, total testosterone and total cholesterol were compared between the cohort of men using statins and the cohort of men who did not indicate current statin use. In multivariate regression analysis we controlled for age, BMI, and race. RESULTS The mean age of the population was 60.7 years. Men receiving statin medication were older and had a higher mean BMI compared to men not on statins (p<0.001). Serum testosterone levels in patients on statin medications were significantly lower than in patients not on statins (p<0.001). Mean total cholesterol levels were similar between the two groups (p=0.229). Mean serum PSA level was 1.56 ng/ml in patients on statin medications and 1.48 ng/ml in patients not on statin (p=0.120). In subgroups of patients with normal levels of cholesterol and testosterone and normal BMI, there was also no difference in terms of serum PSA levels between patients on statin medication and patients not on statins (p=0.534). After adjusting for significant covariates (age, BMI, and race), statin use was shown to have a significant association with lower mean PSA (p = 0.008) and lower mean testosterone (p<0.001) and similar total cholesterol (p= 0.083). Of the 1379 men receiving statin medications, 94 (6.8%) had serum PSA levels greater than 4 ng/ml, whereas of the 3524 men not taking statin, 218 (6.1%) had serum PSA levels greater than 4 ng/ml (p=0.416). CONCLUSIONS Although use of statins may lower serum PSA levels, its clinical impact is limited. It may not be necessary to determine a different PSA cutoff level for patients on statin medications. © 2010 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 183Issue 4SApril 2010Page: e715-e716 Advertisement Copyright & Permissions© 2010 by American Urological Association Education and Research, Inc.MetricsAuthor Information Bulent Akduman Zonguldak, Turkey More articles by this author Daniel J. Tandberg Aurora, CO More articles by this author Colin O'Donnell Aurora, CO More articles by this author Alexa Hughes Aurora, CO More articles by this author Mark A. Moyad Ann Arbor, MI More articles by this author E. David Crawford Aurora, CO More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ..." @default.
• W1995115699 created "2016-06-24" @default.
• W1995115699 creator A5005116281 @default.
• W1995115699 creator A5014213335 @default.
• W1995115699 creator A5026670425 @default.
• W1995115699 creator A5039782870 @default.
• W1995115699 creator A5048958529 @default.
• W1995115699 creator A5070830816 @default.
• W1995115699 date "2010-04-01" @default.
• W1995115699 modified "2023-09-25" @default.
• W1995115699 title "1844 ASSOCIATION OF STATIN USE TO SERUM PROSTATE SPECIFIC ANTIGEN LEVELS IN A SCREENING POPULATION" @default.
• W1995115699 doi "https://doi.org/10.1016/j.juro.2010.02.1783" @default.
• W1995115699 hasPublicationYear "2010" @default.
• W1995115699 type Work @default.
• W1995115699 sameAs 1995115699 @default.
• W1995115699 citedByCount "0" @default.
• W1995115699 crossrefType "journal-article" @default.
• W1995115699 hasAuthorship W1995115699A5005116281 @default.
• W1995115699 hasAuthorship W1995115699A5014213335 @default.
• W1995115699 hasAuthorship W1995115699A5026670425 @default.
• W1995115699 hasAuthorship W1995115699A5039782870 @default.
• W1995115699 hasAuthorship W1995115699A5048958529 @default.
• W1995115699 hasAuthorship W1995115699A5070830816 @default.
• W1995115699 hasConcept C121608353 @default.
• W1995115699 hasConcept C126322002 @default.
• W1995115699 hasConcept C143998085 @default.
• W1995115699 hasConcept C201903717 @default.
• W1995115699 hasConcept C2775941076 @default.
• W1995115699 hasConcept C2776839432 @default.
• W1995115699 hasConcept C2779279991 @default.
• W1995115699 hasConcept C2780192828 @default.
• W1995115699 hasConcept C2781406297 @default.
• W1995115699 hasConcept C2908647359 @default.
• W1995115699 hasConcept C29456083 @default.
• W1995115699 hasConcept C512399662 @default.
• W1995115699 hasConcept C71924100 @default.
• W1995115699 hasConcept C72563966 @default.
• W1995115699 hasConcept C99454951 @default.
• W1995115699 hasConceptScore W1995115699C121608353 @default.
• W1995115699 hasConceptScore W1995115699C126322002 @default.
• W1995115699 hasConceptScore W1995115699C143998085 @default.
• W1995115699 hasConceptScore W1995115699C201903717 @default.
• W1995115699 hasConceptScore W1995115699C2775941076 @default.
• W1995115699 hasConceptScore W1995115699C2776839432 @default.
• W1995115699 hasConceptScore W1995115699C2779279991 @default.
• W1995115699 hasConceptScore W1995115699C2780192828 @default.
• W1995115699 hasConceptScore W1995115699C2781406297 @default.
• W1995115699 hasConceptScore W1995115699C2908647359 @default.
• W1995115699 hasConceptScore W1995115699C29456083 @default.
• W1995115699 hasConceptScore W1995115699C512399662 @default.
• W1995115699 hasConceptScore W1995115699C71924100 @default.
• W1995115699 hasConceptScore W1995115699C72563966 @default.
• W1995115699 hasConceptScore W1995115699C99454951 @default.
• W1995115699 hasIssue "4S" @default.
• W1995115699 hasLocation W19951156991 @default.
• W1995115699 hasOpenAccess W1995115699 @default.
• W1995115699 hasPrimaryLocation W19951156991 @default.
• W1995115699 hasRelatedWork W1911010690 @default.
• W1995115699 hasRelatedWork W2002790620 @default.
• W1995115699 hasRelatedWork W2003514470 @default.
• W1995115699 hasRelatedWork W2016723208 @default.
• W1995115699 hasRelatedWork W2071351450 @default.
• W1995115699 hasRelatedWork W2147707434 @default.
• W1995115699 hasRelatedWork W2415732710 @default.
• W1995115699 hasRelatedWork W2419241430 @default.
• W1995115699 hasRelatedWork W2999207890 @default.
• W1995115699 hasRelatedWork W2129613843 @default.
• W1995115699 hasVolume "183" @default.
• W1995115699 isParatext "false" @default.
• W1995115699 isRetracted "false" @default.
• W1995115699 magId "1995115699" @default.
• W1995115699 workType "article" @default.